Muscle cell grafting for the treatment and prevention of heart failure

• Published in: Journal of cardiac failure Vol. 8; no. 6; pp. S532 - S541
• Main Authors: Murry, Charles E., Whitney, Marsha L., Reinecke, Hans
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2002
• Subjects: Animals; Cell Transplantation; Connexins - metabolism; Heart Failure - prevention & control; Heart Failure - therapy; Muscle, Skeletal - cytology; Myocardium - pathology; Myocytes, Cardiac - transplantation
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1054/jcaf.2002.129268

Background: The review aims to highlight recent advances in cardiac and skeletal muscle cell grafting for myocardial infarct repair. Results: Fetal and neonatal cardiomyocytes form new myocardium in normal or injured hearts, and this new myocardium differentiates toward an adult phenotype. Unfortunately, formation of new myocardium is limited by graft cell death, in large part because of ischemic injury. In contrast, skeletal myoblasts are ischemia-resistant and form larger grafts of mature skeletal muscle in the injured heart. Although contractile under field stimulation, skeletal muscle grafts do not express gap junction proteins and remain electrically insulated, suggesting they may not beat with host myocardium. When placed in coculture, however, cardiac and skeletal muscle form synchronously beating networks, where cardiomyocytes capture and pace skeletal muscle cells via intercalated disk-like structures containing gap junctions. This suggests that engineering skeletal muscle to express gap junction proteins in vivo may induce similar coupling with host myocardium. One major challenge to myocardial repair is getting sufficient graft cell mass without risking a tumor-like overgrowth. Recent experiments suggest it may be possible to control skeletal muscle graft size using a small, synthetic ligand, which activates the fibroblast growth factor signaling pathway only in genetically modified graft cells. Finally, a review of functional studies is presented that provides clear evidence that skeletal myoblast grafting is beneficial by limiting remodeling of the heart after infarction. Conclusion: Given that clinical trials of skeletal myoblast grafting for myocardial repair are under way, it will be critically important to determine if these cells beat after grafting in the heart.